Molecular Classification of Triple-Negative Breast Cancer

Overview

Journal J Breast Cancer

Date 2016 Oct 11

PMID 27721871

Citations 57

Authors

Sung Gwe Ahn

Seung Jun Kim

Cheungyeul Kim

Joon Jeong

Affiliations

Soon will be listed here.

Abstract

Tumor heterogeneity of triple-negative breast cancer (TNBC) has been the main barrier in conquering breast cancer. To dissect the molecular diversity of TNBC and discover therapeutic targets for TNBC, the molecular classification of TNBC is a prioritized issue in research area. Accordingly, recent studies have been successful in classifying TNBC into several distinct subtypes with specific biologic pathways. Despite the different methodologies used and varied number of final subtypes, these studies identically suggested that TNBC consists of four major subtypes: basal-like, mesenchymal, luminal androgen receptor, and immune-enriched. By reviewing these methods of classifications of TNBC, we highlight the unmet need to develop a molecular classifier suited for TNBC.

Citing Articles

Management of triple-negative breast cancer by natural compounds through different mechanistic pathways.

Kaleem M, Thool M, Dumore N, Abdulrahman A, Ahmad W, Almostadi A Front Genet. 2024; 15:1440430.

PMID: 39130753 PMC: 11310065. DOI: 10.3389/fgene.2024.1440430.

IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.

Wu M, Zhang L, Pi L, Liu L, Wang S, Wu Y Cell Oncol (Dordr). 2024; 47(5):1797-1809.

PMID: 38888849 DOI: 10.1007/s13402-024-00961-7.

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.

Xiong N, Wu H, Yu Z Front Oncol. 2024; 14:1405491.

PMID: 38863622 PMC: 11165151. DOI: 10.3389/fonc.2024.1405491.

Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.

Jezequel P, Lasla H, Gouraud W, Basseville A, Michel B, Frenel J Breast Cancer. 2024; 31(5):825-840.

PMID: 38777987 DOI: 10.1007/s12282-024-01597-z.

Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.

Qian K, Liu Q Transl Breast Cancer Res. 2024; 4:16.

PMID: 38751461 PMC: 11093071. DOI: 10.21037/tbcr-23-17.

References

Nguyen P, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N . The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer. 2013; 109(8):2248-58. PMC: 3798957. DOI: 10.1038/bjc.2013.550. View

Murria Estal R, Palanca Suela S, de Juan Jimenez I, Alenda Gonzalez C, Egoavil Rojas C, Garcia-Casado Z . Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer. Fam Cancer. 2016; 15(2):193-200. DOI: 10.1007/s10689-015-9864-2. View

Hu X, Zhang J, Xu B, Cai L, Ragaz J, Wang Z . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015; 16(4):436-46. DOI: 10.1016/S1470-2045(15)70064-1. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M . Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56. DOI: 10.1016/S1470-2045(14)70160-3. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

Ahn S, Lee H, Lee H, Ah Lee S, Lee S, Leem S . Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score. Int J Mol Sci. 2013; 14(12):23685-99. PMC: 3876071. DOI: 10.3390/ijms141223685. View

Lehmann B, Bauer J, Schafer J, Pendleton C, Tang L, Johnson K . PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014; 16(4):406. PMC: 4187324. DOI: 10.1186/s13058-014-0406-x. View

10.

OShaughnessy J, Schwartzberg L, Danso M, Miller K, Rugo H, Neubauer M . Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014; 32(34):3840-7. DOI: 10.1200/JCO.2014.55.2984. View

11.

Abramson V, Lehmann B, Ballinger T, Pietenpol J . Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2014; 121(1):8-16. PMC: 4270831. DOI: 10.1002/cncr.28914. View

12.

Lehmann B, Pietenpol J . Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2013; 232(2):142-50. PMC: 4090031. DOI: 10.1002/path.4280. View

13.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

14.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

15.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

16.

Masuda H, Baggerly K, Wang Y, Zhang Y, Gonzalez-Angulo A, Meric-Bernstam F . Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013; 19(19):5533-40. PMC: 3813597. DOI: 10.1158/1078-0432.CCR-13-0799. View

17.

Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W . Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015; 17:43. PMC: 4389408. DOI: 10.1186/s13058-015-0550-y. View

18.

Haffty B, Yang Q, Reiss M, Kearney T, Higgins S, Weidhaas J . Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24(36):5652-7. DOI: 10.1200/JCO.2006.06.5664. View

19.

Wendt M, Taylor M, Schiemann B, Sossey-Alaoui K, Schiemann W . Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res. 2014; 16(2):R24. PMC: 4053226. DOI: 10.1186/bcr3623. View

20.

Gucalp A, Tolaney S, Isakoff S, Ingle J, Liu M, Carey L . Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013; 19(19):5505-12. PMC: 4086643. DOI: 10.1158/1078-0432.CCR-12-3327. View